|Last Price||Today's Change||52-Week Range||Trading Volume|
|0.12 CAD||0.00 (+4.35%)||0.065 - 1.54||1.2 million (Below Avg)|
Market data as of 2:44PM 10/06/15. Quotes are delayed by at least 15 min.
Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
PR Newswire - Monday 09/28/2015 11:00 AM ET
Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
PR Newswire - Friday 09/25/2015 4:30 PM ET
Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
PR Newswire - Thursday 09/24/2015 9:00 AM ET
Aeterna Zentaris Announces Amendment to Series B Warrants
PR Newswire - Monday 09/21/2015 9:00 AM ET
|Revenue Growth (1yr)||--|
|Net Income Growth (1yr)||--|
Data is delayed by at least 15 min.